^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Published date:
11/17/2020
Excerpt:
We report efficacy for response-evaluable pts (REP) with RET+ MTC and safety for all pts who initiated pralsetinib...In 79 REP with RET+ MTC (mutation: 61% M918T, 28% C634X, 4% V804X, 8% other), ORR was 65% (95% CI 53–75; n=51/79, 5% complete response [CR]; 59% partial response [PR; 1 pending confirmation]).Pralsetinib demonstrated potent and durable clinical activity in RET+ MTC.
Trial ID: